Invest now
Cohance Lifesciences share price
High risk
You have to be logged in to add this to Watchlist.- ₹446.00(1.40%)August 7, 2026 15:29:58 PM IST
- NSE
- BSE
- Vol : 3.99 M (NSE + BSE)Last 20 day avg : 943.13 K
Cohance Lifesciences is trading 1.40% upper at Rs 446.00 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 449.00 & 433.00. There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of -24.12 Crores in its last quarter.Listed peers of Cohance Lifesciences include Sun Pharmaceutical Industries (0.26%), Divi's Laboratories (-0.52%), Torrent Pharmaceuticals (-0.26%).The Mutual Fund holding in Cohance Lifesciences was at 18.21% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Cohance Lifesciences was at 6.50% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 07 Aug 2026, 06:16 PM IST
- BetaHigh volatility1.23Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.10The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation-2.72The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Cohance Lifesciences News
Cohance Lifesciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,949.00 | 0.26 | 4,67,619.37 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,248.50 | -0.52 | 2,18,971.76 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,952.00 | -0.26 | 1,88,351.43 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,472.00 | -0.20 | 1,18,914.83 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,115.20 | 0.81 | 1,11,241.63 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allCohance Lifesciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-02-12 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-05-28 | Audited Results |
About the company Cohance Lifesciences
- IndustryBiotechnology & Drugs
- ISININE03QK01018
- BSE Code543064
- NSE CodeCOHANCE
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based company focused on global contract development and manufacturing organization (CDMO) platform. The Company specializes in providing end-to-end solutions across the molecule's lifecycle from early-stage development to large-scale commercialization- with a marquee customer base across pharmaceuticals and specialty chemicals. It offers a platform for the lifecycle of small molecule active pharmaceutical ingredient (API) development and manufacturing. Its Integrated Small Molecule Solutions offers good manufacturing practice (GMP)-grade manufacturing solutions and provides small molecule APIs, advanced intermediates and starting materials. Its APIs commercial product line includes Aripiprazole, Articaine HCl, Atomoxetine HCl, Baclofen, Benserazide, Betahistine DiHCl and others. Its pipeline products include Apixaban, Acotiamide, Dexlansoprazole, Edoxaban, Erdosteine, and others.
Cohance Lifesciences Share Price FAQs
Cohance Lifesciences is trading at 446.00 as on Fri Aug 07 2026 09:59:58. This is 1.40% upper as compared to its previous closing price of 439.85.
The market capitalization of Cohance Lifesciences is 17062.50 Cr as on Fri Aug 07 2026 09:59:58.
The average broker rating on Cohance Lifesciences is Hold. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 1 analysts have given a hold rating
- 2 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Cohance Lifesciences is 1038.00 whereas the 52 wk low is 267.85
Cohance Lifesciences can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: %
- D/E ratio: -
Cohance Lifesciences reported a net profit of 179.23 Cr in 2026.
The Mutual Fund Shareholding was 18.21% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Cohance Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.